SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology | BioSpace
Source Node: 3092730
Time Stamp: Jan 31, 2024
Securities Litigation Reform
Bright Green Corporation to acquire platform technologies from C2 Wellness
Source Node: 3085085
Time Stamp: Jan 25, 2024
Core Scientific, Inc. Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Competitive Position
Source Node: 3081824
Time Stamp: Jan 23, 2024
Core Scientific, Inc. Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Competitive Position
Source Node: 3081271
Time Stamp: Jan 23, 2024
Loop Industries Announces MOU For US$66 Million of Non-Dilutive Financing from Reed Management, as Part of a Joint Venture for European Infinite Loop(TM) Technology Roll-Out
Source Node: 3069838
Time Stamp: Jan 18, 2024
Core Scientific, Inc. Plan of Reorganization Confirmed by Bankruptcy Court
Source Node: 3065959
Time Stamp: Jan 16, 2024
“The Time is Now” to Maximize Human Healthspan: A Discussion with Peter Diamandis, Hans Keirstead, Daniel Kraft and Jane Metcalfe
Source Node: 3057468
Time Stamp: Jan 11, 2024
SeaStar Medical Appoints David A. Green as Chief Financial Officer | BioSpace
Source Node: 3059839
Time Stamp: Jan 10, 2024
Dentsply Sirona to Present at J.P. Morgan Healthcare Conference, Provides Update on Anticipated Full Year 2023 Results | BioSpace
Source Node: 3053350
Time Stamp: Jan 8, 2024
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications | BioSpace
Source Node: 3053353
Time Stamp: Jan 8, 2024
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
Source Node: 3049508
Time Stamp: Jan 5, 2024
Core Scientific, Inc. Announces Full Pay Down of Debtor-in-Possession Financing
Source Node: 3047259
Time Stamp: Jan 4, 2024
Core Scientific, Inc. Announces Full Pay Down of Debtor-in-Possession Financing
Source Node: 3046521
Time Stamp: Jan 4, 2024
Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook | BioSpace
Source Node: 3047941
Time Stamp: Jan 3, 2024
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury | BioSpace
Source Node: 3039348
Time Stamp: Dec 27, 2023
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors | BioSpace
Source Node: 3041042
Time Stamp: Dec 27, 2023